Electronic Labeling Study By GAO Yields “No Consensus,” Avoids Cost Issue
This article was originally published in The Pink Sheet Daily
In study mandated by FDASIA, GAO says there are advantages and disadvantages to switching to an electronic-only system for distributing drug label information, but offers no conclusions.
You may also be interested in...
FDA must place antimicrobial breakpoints that usually appear in labeling on a website so they can be more regularly updated. CDER Director Woodcock said that could become a precedent for other electronic labeling changes.
FY 2016 funding bill is much higher than House and Senate appropriations committee totals.
FDA expresses concerns about providing both paper and electronic versions of prescribing information to health care providers but seeks comments on dual systems anyway.